100 results about "Carcinoma prostate" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention relates to a method for diagnosing a tumour disease in an isolated sample, comprising the amplification of methylated DNA sequences, to a kit for diagnosing a tumour disease, and to the use of the method and / or of the kit for the diagnosis and / or progress control of a malignant tumour disease, in particular of prostate, breast, ovarian or colorectal carcinomas. The invention furthermore relates to a computer program product comprising risk score analysis commands for diagnosing a tumour disease, and to a data processing device.

The invention provides a prostate lesion tissue immunofluorescence detection kit and a detection method, and belongs to the technical field of kits. The kit is prepared from the following raw materials in parts by weight: 40 to 60 parts of TYR-xxxPlus fluorescent dye, 30 to 45 parts of TSA Buffer, 20 to 40 parts of Polymer-HRP monoclonal antibody mouse / rabbit second antibody, 15 to 30 parts of antibody, 5 to 15 parts of Dapi dye liquor, 50 to 70 parts of antibody diluent and 50 to 70 parts of peroxidase confining liquid. According to the kit, a non-biotin amplification system is adopted, so that compared with a traditional double-staining experiment, the experiment time is greatly shortened, and interference of endogenous biotin is effectively avoided. The method is suitable for diagnosis and differential diagnosis of prostate cancer, PIN and AAH of prostate resection specimens, acupuncture biopsy specimens, electric resection specimens and transurethral resection specimens, and is particularly suitable for conventional formalin fixed paraffin embedded sections.

The invention discloses a phosphorylated peptidomimetic compound and a medical application thereof. The invention provides a phosphorylated peptidomimetic compound with a novel structure. Activity research shows that the phosphorylated peptidomimetic compound has excellent Cbl-b inhibitory activity and is an effective Cbl-b inhibitor. Technicians in the field know that Cbl-b overexpression can inhibit T cell immune response, and inhibition of Cbl-b can activate killing of an immune system on tumor cells. Therefore, the phosphorylated peptidomimetic compound or pharmaceutically acceptable salts and solvates thereof provided by the invention can be developed and prepared into drugs for treating diseases (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and other tumors) treated or relieved by inhibiting Cbl-b (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and the like) the medicine prospect is promising.

Compounds of formula (I), pharmaceutical compositions thereof, and kits thereof, are disclosed wherein A1 is C(O) or CHRz1 with Rz1 being OH, amine, imine, halogen, (C1-C5)alkoxy, OC(O)(C1-C5)alkyl, or OSO2-amine; A2 is CH2 or O; R1 is hydrogen, (C1-C5)alkyl optionally substituted with one or more Z substituents, (C1-C5)alkoxy optionally substituted with one or more Z substituents, (C2-C5)alkenyl optionally substituted with one or more Z substituents, (C2-C5)alkynyl optionally substituted with one or more Z substituents, (C3-C8)cycloalkyl, aryl, or heteroaryl; Z is halogen, OH, (C1-C5)alkyl, (C1-C5)haloalkyl, (C1-C5)alkoxy, (C1-C5)haloalkoxy, or amine; R2 is a heterocyclic aromatic ring having 5, 6 or 7 members having at least one N, S and / or O; R3 is a (C1-C5)alkyl substituted with one or more Br, Br76; I, I123, I124, or I131; m is an integer from 0 to 2; n is an integer from 0 to 2; and p is an integer from 0 to 5. Compounds of Formula I are inhibitors of 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) and are for use in the treatment or prevention of steroid hormone dependent disease, such as breast cancer, lung cancer, prostate carcinoma, ovarian cancer, uterine cancer, endometrial cancer and endometrial hyperplasia.

The invention belongs to the technical field of sarcosine detection, and relates to an integrated sarcosine detection device as well as a preparation method, a detection method and application thereof. The device consists of a sample bottle and a double-layer paper chip, wherein the double-layer paper chip is fixed in a bottle cap of the sample bottle; the double-layer paper chip comprises a target recognition layer and a detection layer, the target recognition layer is Whatman 1 # filter paper loaded with SOx / HRP-coated MAF-7 biological composite materials, the detection layer is Whatman 1 # filter paper loaded with TMB color developing agents, and the layers are bonded through water-soluble double-faced adhesive tapes. After a sample is added into the sample bottle, the bottle is turned over, SOx can recognize and oxidize sarcosine to obtain H2O2, after the double-sided adhesive tape is fully reacted and dissolved, HRP oxidizes a substrate TMB in the presence of H2O2 to generate a bright blue product oxTMB, and RGB signals are recorded through a handheld colorimeter. The detection device can be used for quantitatively detecting the sarcosine content of the prostatic cancer marker.

The invention belongs to the technical field of biochemical detection, and particularly relates to a micro-fluidic chip PSMA prostate cancer circulating tumor cell immunoenrichment detection kit and a preparation method thereof. According to the kit, an EpCAM antibody, a Vimentin antibody and a double-site PSMA capture combination are fixed in a chip channel through a streptavidin-biotin system, double enrichment of epithelial and mesenchymal CTCs is achieved, PSMA targets are recognized through combination of an aptamer and the antibody, and the detection specificity and sensitivity are improved. Competitive oligopeptides are further introduced to block non-specific binding sites on the surfaces of leukocytes and reduce false positive. By combining a multiple fluorescent chromosome system and a double-antibody nucleic acid probe signal amplification strategy, accurate recognition and quantification of CTC and PSMA positive cells are realized. The scheme is suitable for early screening, curative effect evaluation and relapse monitoring of prostate cancer, and has a good clinical application prospect.

The invention relates to the technical field of medical imaging processing, in particular to a puncture planning method and system based on prostate multi-modal imaging and a storage medium, and the method comprises the steps: planning a first path taking a prostate cancer area as a target spot in prostate multi-modal imaging; an ultrasonic image of the puncture needle in the advancing process according to the first path is obtained in real time; detecting and segmenting the puncture needle in the ultrasonic image, and determining the positioning information of the tip of the puncture needle; the first path is registered into an ultrasonic image in the prostate multi-mode imaging, and correction information of the advancing process of the puncture needle is determined according to the positioning information of the first path and the needle point of the puncture needle. The prostate cancer puncture path is planned on the basis of prostate multi-mode imaging, guide information is provided for puncture, and the form and positioning information of the puncture needle are accurately positioned through ultrasonic guide in the puncture guide process, so that the planned path is utilized to provide accurate guide or correction information for the puncture process.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure relates to 4'-thio-nucleotides and nucleoside compounds for the treatment of various cancers, such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative tumors and plasma cell neoplasms (myeloma). The abstract is intended to be a scanning tool for the purpose of searching in a specific field and is not intended to limit the present invention.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The application provides a prostate cancer biochemical recurrence prognosis risk prediction model based on fatty acid metabolism and cancer cell stemness genes and a construction method thereof, wherein the construction method comprises the following steps: S1: data collection: obtaining prostate cancer sample transcriptome data with biochemical recurrence information from a database, and dividing the data into a model training set and a model test set; S2: stemness score analysis; S3: fatty acid metabolism score analysis; S4: based on the analysis results of S2 and S3, identifying a co-expression gene module related to fatty acid metabolism and stemness characteristics in prostate cancer by a co-expression similarity algorithm and a hierarchical clustering algorithm, and obtaining a fatty acid metabolism and stemness-related gene set; S5: constructing a prostate cancer BCR prognosis risk prediction model; S6: constructing a nomogram model; S7: extracting RNA of a to-be-tested sample, constructing a cDNA library, quantifying the expression of the above genes, and calculating the prognosis risk level of prostate cancer through the expression level.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.

Provided are the use of a specific polypeptide in the preparation of a drug for treating and preventing prostate cancer, and the use of the specific polypeptide in the preparation of an immune inducer. The specific polypeptide is derived from TRPM8 protein, and has a good effect on the treatment and prevention of prostate cancer in each stage, especially androgen-independent prostate carcinoma.

This invention discloses a robotic multi-needle puncture trajectory planning method for prostate cancer. By acquiring two-dimensional ultrasound images and spatial positioning data of the prostate, the coordinates of three-dimensional feature points of obstacles such as blood vessels and the pubic bone are obtained. The tumor contour is extracted using a combination of manual delineation and an improved target detection algorithm to complete three-dimensional reconstruction of the prostate and tumor, as well as implicit function modeling of obstacles, constructing a personalized three-dimensional surgical environment. This method employs a progressive planning strategy, solving for a collision-free reachable workspace for each needle, optimizing the needle insertion trajectory with the shortest path and minimal trauma as objectives, and establishing a tissue deformation compensation model to correct target point offset. Simultaneously, the implanted puncture needles are used as dynamic obstacle iterative update constraints to achieve cyclical optimization of the multi-needle trajectory. Finally, a six-degree-of-freedom robotic arm equipped with a needle guide device completes precise positioning and puncture assistance, achieving orderly, collision-free multi-needle implantation. This invention effectively improves puncture positioning accuracy and surgical safety, reduces manual intervention, and provides an automated, high-precision trajectory planning solution for prostate particle implantation.

Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.

Antibody drug conjugate (ADC) comprising a drug moiety conjugated to antibody or antigen binding fragments thereof that bind to TROP2 disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The ADC of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the ADC disclosed herein can include carcinomas, such as lung cancer, breast cancer, head-and-neck cancer, esophagus cancer, stomach cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervix cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer and oral cancer.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, gastrointestinal cancer, pancreatic cancer, prostate cancer, stromal cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The present application relates to a kind of MOF for prostate cancer noninvasive screening @Os nanoenzyme and its preparation method, application.First, zirconium source, 2,2-pyridine-5,5-dicarboxylic acid is dissolved in N,N-dimethylformamide and the like organic solvent, then the two solutions obtained are mixed in proportion, then pH regulator is added and shaken, the obtained mixture is heated to carry out solvothermal reaction, reaction is separated and purified to obtain MOF;MOF prepared is dispersed in solvent, then osmium source, reducing agent is added and heated to carry out reduction reaction, reaction is separated and purified to obtain MOF @Os nanoenzyme.The MOF @Os nanoenzyme prepared by the method of the present application has a polyhedral structure, and the particle size is 500-1200nm, which has excellent peroxidase-like catalytic activity and almost no oxidase-like activity, and has important application value in early noninvasive diagnosis and bedside real-time detection of prostate cancer.

The invention discloses a preparation method and application of a prostate cancer tissue single-cell suspension. The preparation method of the prostate cancer tissue single-cell suspension comprises the following steps: S1, tissue pretreatment: putting a prostate cancer tissue sample into a low-temperature pretreatment buffer solution, and cutting the prostate cancer tissue sample into tissue fragments; s2, circular enzymolysis: mixing the tissue fragments with a composite enzymatic hydrolysate, and performing digestion for multiple rounds under an oscillation condition; after each round of digestion, collecting supernate into a stop solution containing serum, repeatedly digesting the remaining tissues for multiple times, and combining the supernate to obtain a cell crude suspension; wherein the composite enzymatic hydrolysate contains collagenase, protease, nuclease, an androgen receptor stimulant and / or a ROCK inhibitor; and S3, sequentially carrying out separation and purification on the cell crude suspension through filtration and density gradient centrifugation to obtain the prostate cancer tissue single-cell suspension.

The invention discloses an application of a dihydroisoflavone derivative. Specifically, the invention provides application of a compound shown as a formula I or pharmaceutically acceptable salt thereof in preparation of an STAT3 inhibitor. The compound and STAT3 protein have high affinity, and the compound shows good activity on human cancer cells, especially on one or more of prostate cancer, head and neck cancer and human tongue squamous cell carcinoma at the cellular level, has the potential of being prepared into novel antitumor drugs and has good market prospects. # imgabs0 #

Provided is a use of an interleukin (IL) complex in preparation of drugs for treating lung cancer, liver cancer, sarcoma, colorectal cancer, pancreatic cancer, prostate cancer, and melanoma in a subject in need thereof. Compared with wild-type IL-2, the provided IL complex can more strongly activate tumor-killing immune cells such as CD8+ T cells and NK cells and can also be less likely to activate the growth of Treg cells for inhibiting an immune response, has more excellent drug administration convenience, can achieve the effect of better inhibiting the growth and reproduction of tumor cells in an acceptable toxic dose of organisms, and can inhibit the growth of tumor cells of more types of tumors.

The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and / or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.

Provided are a novel DNA methylation marker TAGMe-5 for tumor identification and a use thereof. The tumor marker TAGMe-5 shows a significant DNA methylation difference in para-carcinoma tissues and carcinoma tissues, the difference has remarkable statistical significance, and the difference is shown in a plurality of tumors such as solid tumors and non-solid tumors. The solid tumors comprise lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, a biliary tract tumor, etc. The non-solid tumors comprise a blood system tumor, lymphoma, etc. Therefore, the tumor marker can be used for screening, molecular diagnosis, prognosis, and therapeutic effect evaluation for clinical multi-tumors (Pan-cancer).

Disclosed are a tumour marker aquaporin 2 protein and an application thereof, belonging to the fields of tumour detection and molecular targeted therapy. The present invention comprises applications of the aquaporin 2 protein in the following functions: (1) as a new tumour marker used for the early diagnosis and prognostic determination of malignant tumours including head and neck squamous cell carcinoma, kidney cancer and prostate cancer; (2) inhibiting tumour cell proliferation; (3) inhibiting tumour cell migration; (4) inhibiting animal transplant tumour model growth. Targeted therapy which uses the aquaporin 2 protein as a biomarker, as in the present invention, provides new ideas for the treatment of malignant tumours such as head and neck squamous cell carcinoma, kidney cancer and prostate cancer.

Prostate treatment using fluid stream to resect prostate tissue, thereby relieving symptoms of conditions such as BPH, prostatitis, and prostatic carcinoma. A device having a fluid delivery element is positioned within a lumen of the urethra within the prostate. A fluid stream is directed outwardly from the fluid delivery element toward a wall of the urethral lumen. The fluid delivery element is moved to scan the fluid stream over the wall to remove a volume of tissue surrounding the lumen. The fluid may be combined with therapeutically active substances or with substances that increase resection efficiency. Fluid force may be adjusted to provide selective tissue resection such that soft tissue is removed while harder tissue is left undamaged. In order to gain a working space within the urethra, another fluid may be introduced to insufflate the urethra in the region of treatment.

The present invention relates to a 2-amino-substituted derivative (Formula I) or an ethylenediamine-substituted derivative (Formulas II and III) of hypocrellin as a photodynamic drug for treating the following tumors: esophageal cancer, gastric cancer, lung cancer, liver cancer, cholangiocarcinoma, colon cancer cells related to digestive tract tumors; brain cancer, head and neck cancer, tongue cancer, nasal cancer, oral cancer, glioblastoma cells related to head, neck and facial tumors; basal cell carcinoma, squamous cell carcinoma, cutaneous T-cell lymphoma, melanoma cells related to skin tumors; prostate cancer, bladder cancer cells related to genitourinary tumors. At the same time, such derivatives can localize the location of tumor tissues through their own fluorescence and are used for fluorescence-guided surgical resection of tumors.